本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging[1] agent for prostate cancer. Gozellix®, after radiolabeling with 68Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gozellix® is a novel product which provides a longer shelf life of up to six hours and an extended distribution radius compared to existing gallium-based imaging products. The ability to reliably deliver the product much further from its point of production means Gozellix® can reach PET cameras that are currently not served by any PSMA imaging providers, bringing the accuracy and clinical utility of gallium-based imaging to more patients across the U.S. The innovative formulation, which allows for more scalable production, also has the potential to enhance the efficiency, scheduling flexibility and throughput of scanning clinics. Gozellix® builds on the success of Telix's established PSMA-PET imaging agent, Illuccix®, and will be available alongside the first-generation product, providing choice for customers and patients based on their individual needs. In the U.S., the accuracy and sensitivity of PSMA-PET imaging means it has become the standard of care for prostate cancer imaging after initial diagnosis and biochemical recurrence[2]. However, only a relatively small fraction of the 3.4 million men living with prostate cancer in the U.S. have undergone this type of precision medicine scan[3],[4]. Telix believes Gozellix® will help to address these access issues, as it is expected to be eligible for full reimbursement[5] with reduced or no patient co-insurance, meaning it can reach more patients, particularly in underserved populations. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, "Securing FDA approval for Gozellix is a major win for prostate cancer patients, who gain enhanced access to state-of-the-art 68Ga PSMA-PET imaging. Telix continues to invest in innovation across our portfolio, and Gozellix is a testament to this continuous improvement approach. With the launch of Gozellix, our team is excited to be bringing the new generation of prostate cancer scanning to more American men, delivered with the reliability, service and flexibility that customers have come to expect from Telix." IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Risk for Misinterpretation Image interpretation errors can occur with GOZELLIX PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga-68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence Therapy The performance of GOZELLIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of GOZELLIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation Risks Gallium Ga-68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. Hypersensitivity Reactions to Sulfites Ascorbic Acid Stabilizer contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. ADVERSE REACTIONS The safety of gallium Ga-68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMABCR studies, each receiving one dose of gallium Ga-68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%. DRUG INTERACTIONS Androgen deprivation therapy and other therapies targeting the androgen pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga-68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga-68 gozetotide PET has not been established. Please note that this information is not comprehensive. Please see the Full Prescribing Information here. You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved by the U.S. FDA[6], by the Australian Therapeutic Goods Administration (TGA)[7], by Health Canada[8], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[9], by the Brazilian Health Regulatory Agency (ANVISA)[10], and in multiple countries within the European Economic Area (EEA)[11] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[12]. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[13]. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Imaging of prostate-specific membrane antigen with positron emission tomography.[2] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024.[3] NIH Common Cancer Sites — Cancer Stat Facts. Accessed May 2024.[4] Company analysis based on proprietary and public domain data.[5] Hospital Outpatient Prospective Payment System (OPPS) patients eligible for reimbursed PSMA-PET scanning.[6] Telix ASX disclosure 20 December 2021.[7] Telix ASX disclosure 2 November 2021[8] Telix ASX disclosure 14 October 2022.[9] Telix ASX disclosure 13 February 2025.[10] Telix ASX disclosure 18 March 2025.[11] Denmark, Luxembourg, Malta, the Netherlands and Norway at time of release.[12] Telix ASX disclosure 17 January 2025.[13] Telix ASX disclosure 21 March 2025.
NINGDE, China, March 20, 2025 /PRNewswire/ -- CATL and the Ellen MacArthur Foundation have announced an agreement to accelerate the development of a circular economy for batteries, with CATL becoming a Strategic Partner, and the first renewable technology leader, in the Foundation's Network. Looking ahead, CATL will work towards a global energy circularity commitment, and will collaborate with the Foundation to identify the circular economy opportunity for the entire battery value chain, and build an ecosystem of cross-industrial partners to develop and implement a blueprint for battery circularity. While the industry has long recognized the need to move beyond a 'take-make-waste' approach, translating commitment into reality is complex. The expertise CATL will bring to the Strategic Partnership will be key to establishing a truly circular battery industry. "This Strategic Partnership represents a major step forward in our shared vision of a sustainable energy future," said Sandy Song, CATL's Global Lead for Circular Economy. "By combining our knowledge and innovation capabilities in the battery industry with the Foundation's leadership in the circular economy, we are well-positioned to create a truly circular battery ecosystem. This is not just about environmental responsibility—it's about driving innovation and building a system that benefits industries and communities worldwide." "The rapid growth of renewable energy and electrification offers a unique chance to build circular value chains from the ground up. By embracing a circular economy, businesses can recover valuable resources from first-wave technologies, such as electric vehicles, rather than discarding them," said Joe Murphy, Executive Lead, Network, Ellen MacArthur Foundation. "As the world's foremost producer of batteries for both electric vehicles and energy storage systems, CATL's expertise will be key to establishing a truly circular battery industry and driving the circular economy of the wider energy transition." Speaking at the Foundation's annual Network event in Amsterdam, the Netherlands, Dennis Pan, Chief Sustainability Officer of CATL, emphasized the critical importance of designing batteries with recyclability in mind. CATL has adopted a zero-carbon strategy to prioritize using reusable and renewable materials and facilitate recycling. In 2024, CATL recycled about 130,000 tons of used batteries to produce 17,000 tons of lithium salt.
Debic Celebrates Team Malaysia's Historic Bronze Win at Coupe du Monde de la Pâtisserie 2025 as a Proud Global Supporter and Co-Sponsor. KUALA LUMPUR, Malaysia, March 20, 2025 /PRNewswire/ -- Team Malaysia secured the Bronze medal after competing against 18 of the globe's top pastry teams at The Coupe du Monde de la Pâtisserie 2025. The competition has once again set the global stage for pastry innovation and artistry, challenging the world's best pastry chefs to push the boundaries of creativity, technique and craftsmanship. The Malaysian chefs impressed the esteemed panel of judges with their intricate and innovative pastry creations inspired by the theme 'National Heritage'. (From left to right): Ms. Stella Yew, Head of Food Service, FrieslandCampina Professional, Chef Foo Yi Qing, Chef Fong Kah Mun, Coach Chef Loi Ming Ai, Chef Tyler Tan, and Mr. Majid Zaman, Business Development Director, QSR Asia & Horeca & Bakery Philippines, FrieslandCampina Professional The 2025 Bronze Medal-winning team consists of Chef Loi Ming Ai, team coach, Chef Foo Yi Qing, sugar candidate, Chef Tyler Tan, ice candidate and Chef Fong Kah Mun, chocolate candidate. Their award-winning masterpiece was executed with remarkable precision and artistry over two intense days of competition. The team's ability to blend technical skill with storytelling through pastry set them apart on the global stage. Mr. Majid Zaman, Business Development Director, QSR Asia & Horeca & Bakery Philippines, FrieslandCampina Professional, shared, "Winning Bronze at the Coupe du Monde de la Pâtisserie 2025 is a huge achievement, and we couldn't be prouder of Team Malaysia who is sponsored by Debic and was also coached by Debic's brand ambassador, Chef Loi Ming Ai. Competing at this level takes extraordinary skill, dedication, and creativity, and they've shown the world what Malaysian pastry talent is all about. At FrieslandCampina Professional, we understand the demands of top chefs, bakers, and pastry professionals—consistency, quality, and reliability matter. That's why Debic is crafted specifically for professionals, helping them bring their ideas to life with ease and confidence. This win is not just a moment of pride for the team but for Malaysia's entire pastry industry, and we're excited to continue supporting chefs as they push the boundaries of excellence." Speaking on behalf of the team, Coach Chef Loi Ming Ai expressed their pride in representing Malaysia on the world stage, "Standing among the top three teams in the world is an incredible honour. Competing at this level requires precision, creativity, and perseverance, and we are proud to have showcased Malaysia's rich heritage through our creations. This achievement is not just for us—it is for the entire Malaysian pastry community, and we hope it inspires future generations to aim even higher." For over 20 years, Debic, the 100-year-old premium European dairy brand crafted for professional hands, has been a passionate global supporter of this prestigious competition. As a proud sponsor of Team Malaysia 2025, Debic is thrilled to celebrate the team's remarkable achievement—winning the Bronze Medal and securing Malaysia's place among the top three pastry teams in the world. As Debic's brand ambassador, Chef Loi Ming Ai has showcased his commitment to supporting pastry professionals in Malaysia and beyond. His experience and expertise also reflect Debic's values of quality, innovation, and reliability. As Team Malaysia's sponsor, Debic continues to provide chefs with high-quality dairy solutions to enhance their work and compete at the highest level. Building on Malaysia's strong legacy at the Coupe du Monde de la Pâtisserie, this year's team aimed to match the nation's success in 2019, when Malaysia took home the championship title with its groundbreaking creations. That historic victory became a moment of national pride, with Chef Otto Tay and Chef Loi Ming Ai as Debic's brand ambassadors—further reinforcing its dedication to supporting and elevating pastry excellence in Malaysia. About FrieslandCampina Every day, FrieslandCampina provides millions of consumers all over the world with food that is rich in valuable nutrients. With annual revenue of 12.9 billion euros, FrieslandCampina is one of the world's five largest dairy companies, supplying consumer and professional products, as well as ingredients and half-finished products to the food industry and the pharmaceutical sector around the world. FrieslandCampina has offices in 36 countries and its products are available in more than 100 countries. The Company is fully owned by Zuivelcoöperatie FrieslandCampina U.A, with 14,183 member dairy farmers in the Netherlands, Germany and Belgium—making it one of the world's largest dairy cooperatives. For more information, please visit: www.frieslandcampina.com About FrieslandCampina Professional FrieslandCampina Professional is a division of FrieslandCampina that provides dairy and dairy alternatives-based offerings for chefs and food professionals. FrieslandCampina Professional draws from their in-depth market understanding and collaborative partnerships to provide solutions dedicated to nourishing food heroes. The offerings from FrieslandCampina Professional simplify the lives of food professionals through innovative products and committed partnerships for shared success. About Dutch Lady Milk Industries Berhad Incorporated in 1963, Dutch Lady Milk Industries Berhad (DLMI) is a leading dairy company in Malaysia. It is owned by one of the largest dairy cooperative companies in the world, FrieslandCampina, a Dutch multinational dairy company. DLMI was the first milk company to be listed on Bursa Malaysia in 1968, and the first to introduce Formulated Milk Powder for Children in Malaysia in 1988. Staying true to our purpose of Nourishing Our Planet and People in Every Stage of Life, DLMI manufactures and sells a wide range of quality dairy products for the home and export market. Through a unique collaboration between FrieslandCampina and four international research teams/universities, we initiated the South East Asian Nutrition Surveys (SEANUTS) study in 2009, involving four countries – Malaysia, Indonesia, Vietnam and Thailand. SEANUTS is the largest and most extensive nutrition and health study ever done in South-East Asia, wherein 16,744 children up to 12 years old were surveyed over a four-year period. The follow-up SEANUTS II was conducted between 2019 – 2021 involving 14,000 children in the four countries. More information can be found at www.dutchlady.com.my About DebicDebic is a professional dairy brand under FrieslandCampina Professional. With over 100 years of dairy expertise, Debic provides chefs, pastry chefs, and other food professionals with a solid base of premium European dairy products. With a range of high-quality cream, butter, and dessert products, Debic offerings are made for professionals, enriching them with the best in quality, convenience, and inspiration.
NEW YORK and MUMBAI, India , March 19, 2025 /PRNewswire/ -- Fractal (www.fractal.ai), a global provider of enterprise AI solutions and services to Fortune 500® companies, today announced a $20 million strategic investment in one of its product companies, Asper.ai, a purpose-built AI for growth platform for consumer goods and manufacturing. The funding aims to power Asper's next phase of growth, focusing on scaling its product development and expanding its enterprise customer base across the globe. Speaking about the investment, Pranay Agrawal, Co-Founder and CEO, Fractal, said, "Asper has demonstrated exceptional growth and innovation in just three years. We are thrilled to continue our partnership with Asper's team to drive the next phase of growth. The phased investment will fuel Asper's vision, unlocking new opportunities for enterprise customers." Asper.ai Co-founder & CEO, Mohit Agarwal said, "Last 3 years have been a thrilling and rewarding journey of building an AI platform in midst of all the tech innovation. Consumer goods leaders need more than AI—they need an ally that scales with their operations, speaks their language, and turns data into actionable decisions. This investment from Fractal further enables us in building our autonomous growth AI platform, attract experienced talent, and expand our product offerings to meet the growing demand for cutting-edge AI platforms." Anuj Kaushik, Co-founder & Chief Commercial Officer, Asper.ai shared, "The market has responded well to our product capabilities. Building the capability in-house requires significant investment in AI talent, infrastructure, and ongoing model training, alongside deep domain expertise. Our platform eliminates these barriers, offering purpose-built vertically integrated AI solutions that delivers speed-to-value." Asper.ai remains committed to driving innovation and delivering transformative AI solutions for enterprises worldwide. With a strong foundation and continued investment, the company is poised to expand its impact, and enhance value for its growing customer base. About Asper.ai Asper.ai enables interconnected and automated decisions leveraging its proprietary AI for growth platform across 4 growth levers – Demand Forecasting and Planning, Revenue Growth Management, Inventory Planning, and Sales Execution. By changing the way decisions are made, Asper.ai unlocks growth and transforms organisations into adaptive intelligent enterprises. Asper has built a multidisciplinary team across Bengaluru, New York, London, and San Francisco, with a strong focus on customer centricity and culture. About Fractal Fractal is a globally recognized AI company with the vision to power every human decision in the enterprise. Fractal is a trusted partner to some of the most admired Fortune 500® companies. Fractal's businesses include Asper.ai (enabling interconnected decisions for revenue growth), Flyfish (GenAI platform for search & product discovery), and Analytics Vidhya (one of the world's largest data science community). Fractal incubated Qure.ai, a leading player in healthcare AI for efficient identification and care of Tuberculosis, lung cancer and stroke. Fractal currently has 5000+ employees across 18 global locations, including the USA, Canada, UK, Netherlands, Ukraine, India, Singapore, South Africa, UAE and Australia.
New System Combines NVIDIA Power Efficient CPU with Supermicro's Petascale Architecture SAN JOSE, Calif., March 19, 2025 /PRNewswire/ -- GTC 2025 Conference -- Supermicro, Inc. (NASDAQ: SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, announced a new optimized storage server for high-performance software-defined storage workloads. This first-of-its-class storage server from a major Tier 1 provider utilizes Supermicro's system design expertise to create a high-density storage server for software-defined workloads found in AI and ML training and inferencing, analytics and enterprise storage workloads. Supermicro worked closely with NVIDIA and WEKA to enable customers to create power-efficient high-performance storage systems for their AI factories. NVIDIA Grace GPU "The Supermicro Petascale server with the NVIDIA Grace CPU Superchip highlights Supermicro's focus on innovation and customer choice," said Charles Liang, president and CEO of Supermicro. "We have developed the Petascale storage server using the NVIDIA Grace CPU with 144 Arm Neoverse V2 cores enabling high-performance I/O for software-defined storage workloads. We have demonstrated that the system can fully unleash the system's PCIe Gen5 performance SSD bandwidth with linear scalability. Supermicro continues to bring to market the most advanced and optimized storage solutions available." For more information about the new Grace Storage server, please visit www.supermicro.com/en/products/petascale-grace-storage. Utilizing Supermicro's Building Block Solutions® system design strategy, the ARS-121L-NE316R 1U storage system incorporates a symmetrical architecture perfect for scaling AI workloads. The Supermicro Petascale storage server using the energy efficient NVIDIA Grace CPU Superchip, supports 16 hot-swap EDSFF PCIe Gen5 E3.S NVMe drives enabling 983TB raw capacity using 61.44TB SSDs and a rack containing 40 systems provides 39.3PB of raw storage capacity. "We worked closely together on the development and testing of Supermicro's storage server with NVIDIA Grace, giving storage software providers a range of hardware choices to meet different application requirements," said Rob Davis, vice president of storage networking technology at NVIDIA. "This new storage server allows customers to benefit from NVIDIA's innovations in both CPUs and DPUs to accelerate networking protocols, such as GPUDirect Storage, while using less power than comparable x86 servers." Supermicro is collaborating with WEKA, a leader in high-performance storage software for AI, HPC and enterprise data management workloads. The combination of the 144 Arm cores, integrated 960GB of LPDDR5X on the CPU platform, and ability to support two NVIDIA BlueField-3 or ConnectX-8 SuperNICs will unleash the full performance of the WEKA® Data Platform's zero-copy architecture, providing the highest performance with lower power utilization compared with x86-based systems. "WEKA is proud to be collaborating with Supermicro and NVIDIA in creating a high-performance solution optimized for enterprise AI and ML training, analytics, and inferencing," said Nilesh Patel, Chief Product Officer at WEKA. "Initial testing of WEKA Data Platform software running on Supermicro's petascale storage server with the NVIDIA Grace CPU-based pre-production cluster shows significant performance scaling and power efficiency." For more information on the Supermicro storage solutions for AI, please visit: https://www.supermicro.com/en/products/storage. Supermicro at GTC 2025 Supermicro and NVIDIA will present the new Petascale storage server using the Grace CPU in more detail at NVIDIA GTC in San Jose starting on March 17 in an On-Demand session (S74296). About Super Micro Computer, Inc. Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions manufacturer with server, AI, storage, IoT, switch systems, software, and support services. Supermicro's motherboard, power, and chassis design expertise further enables our development and production, enabling next-generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Asia, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling). Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc. All other brands, names, and trademarks are the property of their respective owners.
DataSnipper enters 2025 with significant global momentum — including a 53% increase in customer count in 2024, 6,715% turnover growth, and a US$1 billion valuation, cementing its position as one of Europe’s fastest-growing technology companies. SINGAPORE - Media OutReach Newswire - 19 March 2025 - DataSnipper, the intelligent automation platform for audit and finance, has appointed Siu Wei Lee as Sales Director, Asia Pacific and Japan, marking a key step in its global expansion. Siu Wei will lead DataSnipper’s growth across the region, building on its rapid momentum in Europe and the Americas. Siu Wei Lee, Sales Director, Asia Pacific and Japan, DataSnipper With over 20 years of experience spanning audit and technology, Siu Wei brings deep expertise as both an internal and external auditor, combined with a proven track record driving audit automation and digital transformation. Prior to joining DataSnipper, she led teams at PwC and Wolters Kluwer, delivering audit management and data analytics solutions to the APAC market. DataSnipper expansion targets regional needs Siu Wei’s appointment demonstrates DataSnipper’s deepening commitment to the Asia Pacific region, tailoring its technology and services increasingly to the specific needs of local customers. Her arrival comes as DataSnipper enters 2025 with significant global momentum — including a 53% increase in customer count in 2024, 6,715% turnover growth, and a US$1 billion valuation, cementing its position as one of Europe’s fastest-growing technology companies. In APAC, audit and finance teams face an urgent need for smarter automation. In Singapore, the Accounting and Corporate Regulatory Authority (ACRA), supported by the Ministry of Finance, established the Accountancy Workforce Review Committee to grow the number of professionals in the accounting sector — a challenge seen across the region. Combined with fragmented regulations and rising demand for transparent, efficient reporting, teams are actively seeking better ways to work. DataSnipper’s platform already helps teams in the region - including Crowe, PwC, KPMG, and Grant Thornton - save thousands of hours per year automating extraction, cross-referencing, and validation of data directly within Excel, improving accuracy and audit quality. At Moore Hong Kong, the audit team reduced annual report review times from 2.5 days to just minutes using DataSnipper’s tools. This kind of efficiency gain is critical for teams stretched thin by talent shortages and mounting regulatory pressure across the region. Audit innovation in APAC’s fastest-growing markets “As someone who’s spent 20 years in audit and finance, starting in external audit at PwC, I know the daily grind all too well,” said Siu Wei Lee, Sales Director, Asia Pacific and Japan at DataSnipper. “The document chase, the manual evidence hunts, the constant compliance pressure - I've been in those shoes. It’s exhausting. That’s why I’m so excited to lead DataSnipper in APAC. Our rapidly expanding team and customer localization will make sure we deliver exactly what firms here need, so they can finally shift from paperwork to real insights.'' Vidya Peters, CEO of DataSnipper said, “Bringing in Siu Wei, with her deep audit expertise and local knowledge, in addition to hiring a strong team of customer success and support experts around her, is a clear signal of our commitment to this region. We understand the challenges APAC firms face - from talent shortages to regulatory complexity - and we’re committed to delivering solutions that directly address these challenges.’’ Seamless automation for APAC: DataSnipper on Microsoft Azure As further part of its global expansion, DataSnipper is listed in the Microsoft Azure Marketplace, making it easier for APAC firms to seamlessly adopt the platform within their existing cloud infrastructures. “Listing on Azure Marketplace is a key milestone for DataSnipper’s global growth,” added Peters. “For our customers in Asia Pacific, it means smarter integration of automation into their existing systems without friction.” Hashtag: #DataSnipper #AuditAutomation #AI #AsiaPacifichttps://www.datasnipper.com/https://www.linkedin.com/company/datasnipper/The issuer is solely responsible for the content of this announcement.About DataSnipper DataSnipper is transforming data in the audit and finance industry. Founded in 2017, DataSnipper provides audit and finance teams with an intelligent automation platform to drastically increase the quality and efficiency of audit and finance procedures. DataSnipper is used by over 500,000 audit and finance professionals in 125+ countries and serves all four of the largest global auditing firms: Deloitte, Ernst & Young (EY), KPMG, and PricewaterhouseCoopers. DataSnipper is the fastest-growing tech company in the Netherlands and raised $100 million in Series B, led by Index Ventures at a $1 billion valuation.
A12 藝術空間
Netherlands
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
